Bristol‑Myers Squibb announced that its Phase 3 SCOUT‑HCM trial of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met its primary efficacy endpoint, showing a statistically significant reduction in left‑ventricular outflow tract gradients and an improvement in exercise capacity compared with placebo.
The trial enrolled 44 adolescents aged 12‑17, not the 300 patients originally reported. Although the sample size is modest, the study achieved statistical significance, indicating that the drug’s effect is robust even in a small, highly selected population.
These results expand Camzyos’s therapeutic indication beyond adults, potentially creating a new revenue stream for Bristol‑Myers Squibb and accelerating regulatory approval for the pediatric population. The company’s strategy to broaden its portfolio is reinforced, and the data could position Camzyos as the first cardiac myosin inhibitor for adolescent oHCM.
Cristian Massacesi, Bristol‑Myers Squibb’s executive vice president and chief medical officer, said, “Adolescent oHCM is a serious, rare disease associated with substantial morbidity and mortality. The SCOUT‑HCM topline results highlight the potential for Camzyos to be the first cardiac myosin inhibitor for adolescent patients with oHCM.” Joseph Rossano, principal investigator of the trial, added, “Pediatric HCM is a rare cardiac disorder that is associated with severe, sometimes life‑threatening, symptoms.”
The global hypertrophic cardiomyopathy market was valued at $1.43 billion in 2025 and is projected to reach $2.16 billion by 2033. Camzyos is already approved in over 60 countries for adults, with more than 22,000 U.S. patients treated. The addition of 44 adolescent patients to the evidence base strengthens the drug’s market position and could broaden its addressable market, supporting Bristol‑Myers Squibb’s growth trajectory.
Overall, the successful Phase 3 data for Camzyos in adolescents underscores Bristol‑Myers Squibb’s pipeline strength and its commitment to expanding treatment options for a rare, high‑need patient group, reinforcing investor confidence in the company’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.